Suppr超能文献

基层医疗中流感的抗病毒治疗与预防:德国建议

Antiviral treatment and prophylaxis of influenza in primary care: German recommendations.

作者信息

Wutzler P, Kossow K-D, Lode H, Ruf B R, Scholz H, Vogel G E

机构信息

Institut für Virologie und Antivirale Therapie, Klinikum der Friedrich-Schiller Universität, Hans-Knöll-Strasse 2, D-07745 Jena, Germany.

出版信息

J Clin Virol. 2004 Oct;31(2):84-91. doi: 10.1016/j.jcv.2004.05.009.

Abstract

Antiviral drugs are a valuable supplementation to vaccines for the control and prevention of influenza. In Germany, for treating influenza amantadine, oseltamivir and zanamivir are approved. Amantadine and oseltamivir are also licensed for prophylactic use. On behalf of the Paul-Ehrlich-Society of Germany and the German Association for the Control of Virus Diseases, as two independent scientific societies, the first consensus Conference on the Antiviral Treatment and Prophylaxis of Influenza was held in June 2002. Based on the available data of clinical studies an expert group developed the following recommendations for the appropriate clinical use of the antiviral drugs: (1) since oseltamivir (orally administered) and zanamivir (administered by inhalation) have apparently similar clinical efficacy both drugs can be used alternatively for treatment. (2) Amantadine is not an alternative to the neuraminidase (NA) inhibitors because it is not effective against influenza B viruses, it frequently selects resistant virus mutants and it can cause adverse events. (3) When influenza is prevalent in the community patients with the clinical diagnosis of influenza should be treated with neuraminidase inhibitors if the symptoms are lasting not longer than 48 h. (4) Immunocompetent patients with a non-febrile illness and patients with a symptom history of more than 2 days should not be treated with antiviral drugs. (5) Although there are no data from clinical trials immunocompromised patients should also be treated when influenza has been diagnosed. (6) The prophylactic use of antiviral drugs can be recommended for persons with close contact to acutely ill persons and no recent vaccination against influenza. (7) The use of anti-influenza drugs have to be considered for prophylaxis in pandemics. A precondition for the adequate use of anti-influenza drugs in the primary medical care is the timely information on the local influenza situation delivered by surveillance systems.

摘要

抗病毒药物是控制和预防流感疫苗的重要补充。在德国,金刚烷胺、奥司他韦和扎那米韦被批准用于治疗流感。金刚烷胺和奥司他韦也被许可用于预防。代表德国保罗·埃利希协会和德国病毒病控制协会这两个独立的科学协会,2002年6月召开了第一届流感抗病毒治疗和预防共识会议。基于临床研究的现有数据,一个专家组制定了以下关于抗病毒药物合理临床使用的建议:(1)由于奥司他韦(口服)和扎那米韦(吸入给药)具有明显相似的临床疗效,两种药物均可交替用于治疗。(2)金刚烷胺不是神经氨酸酶(NA)抑制剂的替代品,因为它对B型流感病毒无效,经常会筛选出耐药病毒突变体,并且会引起不良事件。(3)当社区中流感流行时,临床诊断为流感且症状持续不超过48小时的患者应使用神经氨酸酶抑制剂进行治疗。(4)免疫功能正常的非发热疾病患者和症状持续超过2天的患者不应使用抗病毒药物治疗。(5)虽然没有临床试验数据,但免疫功能低下的患者在确诊流感时也应进行治疗。(6)对于与急性病患者密切接触且近期未接种流感疫苗的人,可建议预防性使用抗病毒药物。(7)在大流行期间,应考虑使用抗流感药物进行预防。在初级医疗保健中充分使用抗流感药物的一个前提是监测系统及时提供当地流感情况的信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验